Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain ...
New cash-paying patients can now access Wegovy/Ozempic for $199 a month. Here's what that means for Novo Nordisk stock.
Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback